JANX vs HIVE Comparison

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

HIVE Digital Technologies Ltd is a sustainable-energy-focused digital infrastructure company that provides infrastructure solutions through the operation of Tier-1 and Tier-3 data centers. Its computing power is used for high-performance computing (HPC) and for generating hashrate sold to mining pools for cryptocurrency mining. The Company uses cash flow from its hashrate services business to support the expansion of its AI and HPC operations through its subsidiary. The Company focuses on Canada, Sweden, and Paraguay, where low-cost renewable power supports its operations and expansion. It operates in one segment with two revenue streams: the mining and sale of digital currencies and high-performance computing hosting. The majority of its revenue is generated from Bermuda.